In HSP, integration into such pathways would allow fluid biomarkers like NfL, BD-tau, or GFAP to progress beyond exploratory use and achieve formal recognition as enrichment factors, pharmacodynamic readouts, or even surrogate endpoints. This evidence concerns the gene NEFL and hereditary spastic paraplegia.